Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating Gemcitabine/Nab-Paclitaxel and mFOLFIRINOX in Borderline Resectable Pancreatic Cancer
NCT07043270Phase 2Recruiting
- Sponsor
- Dartmouth Health
- Start
- Sep 2025
- Primary completion
- Jul 2028
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, paclitaxel, mFOLFIRINOX in pancreatic adenocarcinoma (PDAC), sponsored by Dartmouth Health. Started Sep 2025; status: recruiting.
02
Drugs
gemcitabinepaclitaxelmFOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07043270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043270.